Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chronic cough and gastroesophageal reflux disease

Researchers from Rochester, New York, find that 4 to 6 weeks of a proton-pump inhibitor successfully diagnoses and treats most patients with GERD-related cough.

News image

In this study, researchers evaluated proton-pump inhibitor therapy, with or without a prokinetic agent, in the diagnosis and treatment of gastroesophageal reflux disease (GERD)-related cough.

The team performed a review of their experience of 214 patients with a cough of 3 weeks, referred over a 3 and a half year period.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks.
Chest

Their findings are published in the March issue of Chest.

Overall, the team identified 183 patients with chronic cough, these were included in the study. However, 31 patients were disqualified because of abnormal chest radiographic findings, inadequate follow-up, or cough being not the primary complaint.

Of the 183 patients, 56 were identified as having GERD-related cough.

The team prescribed these patients a once-daily dose of a proton-pump inhibitor.

In addition, the team added a prokinetic agent if esophageal dysfunction was suspected, or response was inadequate.

Patients who did not respond underwent 24-hour esophageal pH monitoring.

The research team found that GERD was the single cause of cough in 43% of patients. A further 52% had GERD plus another cause, and 5% patients had GERD with more than 2 causes.

The team also determined that 43% of patients had a cough only, while 57% had other symptoms of GERD.

Overall, proton-pump therapy was successful in 79% of patients.

The team found that 24 patients responded to proton-pump inhibitor therapy, and 18 patients responded when metoclopramide or cisapride was added. The remaining 2 patients responded to a histamine type-2 blocker or cisapride alone.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks, and by 8 weeks in the remaining 6 patients.

The team found that 6 of the nonresponders had aspiration diagnosed by bronchoscopy.

Additionally, 4 patients had fundoplication recommended, and 2 patients responded to alternative interventions.

Drs Robert Poe and Michael Kallay concluded, "4 to 6 weeks of a proton-pump inhibitor alone or in combination with a prokinetic agent successfully diagnoses and treats 4 of 5 patients with GERD-related cough".

"24-hour esophageal pH monitoring will confirm the diagnosis in the others."

"These patients may be candidates for fundoplication."

"Nonresponders often aspirate as an additional aggravating factor."

Chest 2003; 123: 679-84
14 March 2003

Go to top of page Email this page Email this page to a colleague

 25 January 2015

Advanced search
 23 January 2015 
Fecal microbiota transplantation
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 22 January 2015 
NASH and lipid improvements
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Fecal incontinence
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 15 December 2014 
Food allergy and food intolerances
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests
 12 December 2014 
Hospital readmission after colorectal resection
 12 December 2014 
Detecting intestingal damage in Crohn's
 12 December 2014 
SSRIs for noncardiac chest pain

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us